A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);
• The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;
• During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.
Locations
Other Locations
China
Hangzhou First People's Hospital
RECRUITING
Hangzhou
Contact Information
Primary
xiaojuan lai
lai_xiaojuan@vcarepharmatech.com
+8615358160458
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2027-02-22
Participants
Target number of participants: 120
Treatments
Experimental: VC005 Dose A group
Experimental: VC005 Dose B group
Experimental: VC005 Dose C group
Placebo_comparator: VC005 Placebo group
Related Therapeutic Areas
Sponsors
Leads: Jiangsu vcare pharmaceutical technology co., LTD